Actavis Filed to Produce Generic Avinza

Actavis sought FDA approval for a generic version of the pain medication, prompting King Pharmaceuticals to plan a patent lawsuit.

Updated on Sept. 22, 2026 in Healthcare

Isometric editorial illustration showing a glass pharmaceutical ampoule and steel laboratory scale, representing patent and drug manufacturing regulation.
Actavis has filed an FDA application to produce a generic version of the pain medication Avinza, prompting King Pharmaceuticals to prepare for a patent lawsuit. AI Illustration. Upload story photo >

Live Poll

Should drug manufacturers be permitted to legally challenge generic competition to protect their existing patents?

In September 2007, Actavis submitted an application to the US Food and Drug Administration to produce a generic version of the pain medication Avinza. King Pharmaceuticals, which holds the patent, signaled it would pursue legal action to enforce its intellectual property rights.

Why it matters

King Pharmaceuticals maintains a standard protocol to challenge every patent claim filed by generic manufacturers against its product lineup to protect its market position. The dispute highlights the ongoing tensions between drug patent holders and generic firms seeking to enter the market before expiration dates.

King Pharmaceuticals purchased the patent for Avinza for $246 million. While the company saw revenue jump to $35 million in the second quarter of 2007, the patent is not scheduled to expire until November 25, 2017.

The players

Actavis

Actavis is a pharmaceutical company based in Iceland that focuses on the development and manufacturing of generic drugs.

King Pharmaceuticals

King Pharmaceuticals is a United Kingdom-based company that specializes in the acquisition and development of branded prescription pharmaceutical products.

Ligand Pharmaceuticals

Ligand Pharmaceuticals is a biotechnology company headquartered in San Diego that focuses on developing and licensing drug discovery technologies.

The details

Actavis initiated the application process to market a generic version of the pain drug, leading King Pharmaceuticals to prepare for a court battle. The drug maker is expected to initiate formal legal proceedings against the Iceland-based manufacturer within 45 days.

Timeline

  1. Avinza generated $9 million in revenue during Q1 2007.

  2. Avinza revenue rose to $35 million in Q2 2007.

  3. Actavis filed the generic application in September 2007.

  4. King Pharmaceuticals must initiate legal proceedings within 45 days of the filing.

  5. The Avinza patent is currently scheduled to expire on November 25, 2017.

Market Landscape

This dispute reflects the typical competitive environment where branded pharmaceutical companies aggressively protect their revenue streams from generic rivals. The conflict mirrors broader industry trends regarding patent lifecycle management and the strategic defense of high-value medical assets.

The potential legal battle between manufacturers determines whether consumers will have access to lower-cost generic versions of the pain medication. If King Pharmaceuticals successfully defends the patent, patients may continue to face higher costs associated with the branded version of the drug.

The takeaway

Pharmaceutical companies often rely on aggressive patent litigation to extend the exclusivity of their branded drugs. Patients looking for cost savings should monitor court rulings as these decisions directly dictate when generic alternatives reach the pharmacy shelf.

Further reading

For more on industry trends, visit the Healthcare section.

Source note: This article includes information reported by IceNews.

Live Poll

Should drug manufacturers be permitted to legally challenge generic competition to protect their existing patents?